Teleflex (NYSE:TFX) Sets New 12-Month Low - Time to Sell?

Teleflex Incorporated (NYSE:TFX - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $117.24 and last traded at $117.55, with a volume of 496921 shares. The stock had previously closed at $121.11.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wall Street Zen cut shares of Teleflex from a "buy" rating to a "hold" rating in a report on Friday, February 28th. Truist Financial reduced their target price on Teleflex from $140.00 to $137.00 and set a "hold" rating for the company in a research note on Monday, May 5th. Wells Fargo & Company reduced their price objective on Teleflex from $146.00 to $137.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Raymond James cut shares of Teleflex from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Mizuho set a $155.00 target price on shares of Teleflex in a report on Wednesday, April 16th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $164.63.

Teleflex Stock Down 2.9%

The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The firm has a market cap of $5.19 billion, a PE ratio of 23.37, a PEG ratio of 1.73 and a beta of 1.10. The business's 50 day moving average price is $126.61 and its 200 day moving average price is $151.62.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.88 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The business had revenue of $700.67 million during the quarter, compared to analyst estimates of $699.37 million. During the same period in the prior year, the business earned $3.21 earnings per share. The business's revenue was down 5.0% compared to the same quarter last year. On average, equities research analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th were paid a dividend of $0.34 per share. The ex-dividend date was Tuesday, May 20th. This represents a $1.36 annualized dividend and a yield of 1.16%. Teleflex's dividend payout ratio (DPR) is 42.90%.

Institutional Trading of Teleflex

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio acquired a new stake in Teleflex in the 1st quarter valued at approximately $3,040,000. IFM Investors Pty Ltd grew its holdings in shares of Teleflex by 7.8% in the first quarter. IFM Investors Pty Ltd now owns 8,311 shares of the medical technology company's stock valued at $1,148,000 after purchasing an additional 602 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Teleflex by 42.6% in the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company's stock valued at $877,000 after purchasing an additional 1,895 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Teleflex by 15.8% in the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company's stock valued at $233,000 after purchasing an additional 230 shares in the last quarter. Finally, United Services Automobile Association acquired a new position in shares of Teleflex in the first quarter worth $373,000. 95.62% of the stock is owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.